Sponsored Content

Rousselot launches Nextida™ GC, targeting post-meal glucose spikes

First clinical trial results revealed at SupplySide West 2024.

Rousselot, stand #5641, SupplySide West, Las Vegas, October 28-31, 2024.

Irving, Texas, October 8, 2024 – Rousselot, Darling Ingredients’ premier collagen and gelatin brand, will announce the results of the first clinical study behind the company’s latest innovation, Nextida GC. Unveiled earlier this year, the solution is the first ingredient commercialized from the Nextida platform, a range of specific collagen peptide compositions with targeted health benefits to support the body’s balance, naturally.

The trial showed that both a 5- and 10-gram dose of Nextida GC significantly lowered post-meal glucose spikes in healthy individuals when taken orally 30 minutes before a meal, reducing the glucose spike in the blood by 42% on average after the meal.¹

“We’re immensely excited to take our new step toward decoding the collagen molecule with the release of this first study,” said Jeroen Colpaert, Executive Vice President, Rousselot. “With new science supporting our ingredient’s potential for post-meal glucose metabolism in healthy individuals, we are continuing our commitment to offering the health and wellness industry evidence-based solutions that expand what we know about collagen.”

As the event’s official sponsor for glucose management, Rousselot will also be delivering two expert presentations which aim to shed light on this increasingly hot topic. Dr. Janne Prawitt, Scientific Director Health & Nutrition at Rousselot, and Dr. Mariette Abrahams, CEO & Founder at Qina, will discuss the consumer-led metabolic revolution surrounding Nextida GC on Wednesday, Oct. 30, at 12 p.m. – 1 p.m. PST, Lower Level, South Pacific Ballroom D. On Thursday, Oct. 31, at 11 a.m. – 11:20 a.m. PST, at the Supplier Presentation Theater, Dr. Prawitt will provide insights into Nextida GC’s first clinical trial.

Show attendees can connect with Rousselot at booth 5641, to sample Nextida GC and learn more about two recently published, peer-reviewed clinical studies concerning Rousselot's flagship collagen peptide solution Peptan®. One highlights its efficacy in enhancing skin beauty markers² while another demonstrates its effective absorption³ with both reinforcing the scientific foundation behind Peptan’s holistic well-being benefits.

Alternatively, they can visit www.nextida.com and www.rousselot.com to learn more.

[1] Rousselot’s data, first clinical trial involving 16 healthy individuals that took 1 dose of Nextida GC before a meal. Reduced post-meal glucose spike by 43% (5-gram dose) and 40% (10-gram dose).

[2] Vleminckx, S., et al, Influence of collagen peptide supplementation on visible signs of skin and nail health and aging in an East Asian population: a double blind, randomized, placebo-controlled trial, Journal of Cosmetic Dermatology, 2024;00:1–9, https://doi.org/10.1111/jocd.16458

[3] Virgilio, N., et al., Absorption of bioactive peptides following collagen hydrolysate intake: A randomized, double-blind crossover study in healthy individuals, Frontiers in Nutrition, 11, 1416643, 2024. https://pubmed.ncbi.nlm.nih.gov/39149544/

About Rousselot

Rousselot, the health brand of Darling's Ingredients, is a global leader in gelatin- and collagen-based solutions for the food, health & nutrition, biomedical and pharmaceutical industries. Working in partnership with our global customer base, we deliver advanced ingredient solutions that enable innovation, excite today's consumers, and contribute to public health. Through our state-of-the-art operations, extensive technical expertise and sustained scientific research, we help our customers achieve their goals and create world-class products, and we “Reach further together.”